ZYME shares strength on recent FDA approval and acquisitions
ZYME’s recent FDA approval for zanidatamab in GEA is cited as setting a new standard of care and boosting sales projections, alongside growth plans tied to royalties, strategic acquisitions, and R&D.
Recent FDA approval for zanidatamab in GEA has established a new standard of care and lifted sales projections. The business model combines royalty growth, strategic acquisitions and R&D, with flexible capital allocation and a focus on sustainable, risk-adjusted cash flows. Theravance acquisition and a…